We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

40 hedge funds and large institutions have $103M invested in Protagonist Therapeutics in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

5% more funds holding

Funds holding: 38 → 40 (+2)

0.04% less ownership

Funds ownership: 47.74% → 47.7% (-0.04%)

27% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 15

41% less capital invested

Capital invested by funds: $175M → $103M (-$72.2M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
40
Holders Change
+2
Holders Change %
+5.26%
% of All Funds
1%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
7
Increased
11
Reduced
15
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
BlackRock
New York
+$5.57M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.01M
3
PC
Polar Capital
United Kingdom
+$403K
4
PP
PDT Partners
New York
+$290K
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$178K

Top Sellers

1
DCM
DAFNA Capital Management
California
-$1M
2
RCM
RA Capital Management
Massachusetts
-$908K
3
CAM
Cormorant Asset Management
Massachusetts
-$587K
4
Morgan Stanley
Morgan Stanley
New York
-$208K
5
Citigroup
Citigroup
New York
-$121K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$67K – – –
AIG
27
American International Group
New York
$58K +$73.5K +4,564 New
NFA
28
Nationwide Fund Advisors
Ohio
$56K -$9.49K -589 -12%
SO
29
STRS Ohio
Ohio
$30K – – –
Barclays
30
Barclays
United Kingdom
$20K +$22.8K +1,417 +650%
Bank of America
31
Bank of America
North Carolina
$17K +$4.83K +300 +29%
Legal & General Group
32
Legal & General Group
United Kingdom
$13K -$5.09K -316 -24%
TRCT
33
Tower Research Capital (TRC)
New York
$9K +$10.6K +656 New
AIP
34
Ameritas Investment Partners
Nebraska
$7K +$8.28K +514 New
UBS Group
35
UBS Group
Switzerland
$4K -$18K -1,114 -77%
Royal Bank of Canada
36
Royal Bank of Canada
Ontario, Canada
$3K -$1.84K -114 -32%
Citigroup
37
Citigroup
New York
$2K -$121K -7,500 -98%
Creative Planning
38
Creative Planning
Kansas
$2K -$8.06K -500 -74%
MAM
39
Meeder Asset Management
Ohio
$1K +$870 +54 New
BNP Paribas Financial Markets
40
BNP Paribas Financial Markets
France
$269 -$5.51K -342 -94%
DCM
41
DAFNA Capital Management
California
– -$1M -45,586 Closed
1
2

PTGX Hedge Fund Activity: Q1 2017 in Review

40 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2017, worth a combined $103M — down 41% from $175M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new PTGX positions and 1 closed out — a net gain of 6 holders — while 11 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $5.57M. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $1M sold.

  • 40 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2017, up from 38 in Q4 2016.
  • Funds reported $103M of Protagonist Therapeutics stock for Q1 2017, down 41% quarter-over-quarter.
  • 7 funds opened new Protagonist Therapeutics positions in Q1 2017 and 1 closed out, a net change of +6 holders.
  • The largest Protagonist Therapeutics buyer in Q1 2017 was BlackRock, an estimated $5.57M added.
  • The largest Protagonist Therapeutics seller in Q1 2017 was DAFNA Capital Management, an estimated $1M sold.

Based on aggregated 13F filings for Q1 2017.